GlassScriptPhysician profile
Christina E Vera
NPI 1912388158
$2,605.95
in general payments reported to CMS, 2019-2025
26 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $998 · 2020: $184 · 2021: $19.31 · 2022: $438 · 2023: $135 · 2024: $338 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $965.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $384.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $383.09 | 2019-2025 | Breztri, Farxiga |
| Pfizer INC. | $252.43 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $226.79 | 2019-2024 | Dificid |
| Lilly USA, LLC | $193.98 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $189.44 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Abbott Laboratories | $133.74 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $128.58 | 2019-2025 | Otezla, Repatha |
| Amarin Pharma, INC. | $100.32 | 2019-2020 | |
| Astellas Pharma US INC | $98.45 | 2023-2025 | Veozah, Myrbetriq |
| Dexcom, INC. | $69.20 | 2024-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $64.23 | 2022 | |
| Sanofi Pasteur INC. | $62.19 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $47.35 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $42.57 | 2023-2024 | Quviviq |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $39.59 | 2019 | |
| Dynavax Technologies Corporation | $39.43 | 2022-2025 | Heplisav-B |
| Organon LLC | $24.58 | 2024 | |
| Celgene Corporation | $19.05 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $18.18 | 2022 | |
| Renalytix Ai, INC. | $18.06 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Kowa Pharmaceuticals America, INC. | $16.87 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.99 | 2019 | |
| Shire North American Group INC | $14.25 | 2019 | |
| Adlon Therapeutics L.P. | $12.36 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Vera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.